This page summarizes research and treatment ideas for educational purposes only. It is not medical advice, diagnosis, or treatment, and it does not create a doctor-patient relationship. Discuss any change in screening, medication, supplements, or procedures with your cardio-oncologist or other qualified clinician. If you think you may be having a medical emergency, call 911 or seek immediate emergency care.
What's Moving the Needle Right Now
Four recent developments that sharpen long-term surveillance, dose awareness, and prevention conversations for radiation-exposed survivors.
A new adult-cancer cardiovascular-care statement argues that prevention, risk-factor control, toxicity monitoring, and survivorship follow-up should be integrated into routine oncology care. For RICAD survivors, that supports structured follow-up instead of waiting for symptoms decades later.
PubMed abstract →A new review of lung-cancer radiotherapy evidence argues that doses to specific cardiac substructures can predict cardiac risk more precisely than whole-heart dose alone. The practical RICAD takeaway is direct: coronary, heart-base, and ventricular dose deserve attention in survivorship records.
PubMed abstract →Researchers reported an AI model using routine breast-radiotherapy planning CT plus clinical records to estimate cardiovascular risk. It is early, but the direction matters: the same imaging used to plan radiation may eventually help identify who needs tighter heart follow-up.
UBC Okanagan note →Final 20-year data from a major breast-cancer nodal-irradiation trial found lower breast-cancer mortality without an overall-survival gain, as later non-breast-cancer deaths emerged over time. It reinforces a hard survivorship lesson: late cardiac and pulmonary effects need decades of follow-up.
ASCO Post summary →Cardiovascular Interventions for RICAD Survivors
From approved standards to frontier experiments. Always discuss with your cardio-oncologist before changing your protocol.
| Intervention | Status | Mechanism | RICAD Relevance |
|---|---|---|---|
| High-intensity statinsRosuvastatin, Atorvastatin | Approved | LDL reduction + plaque stabilization | Often central to prevention and treatment discussions when radiation-exposed survivors have established CAD or high risk. Dose and intensity should be individualized by a clinician. |
| PCSK9 InhibitorsEvolocumab, Alirocumab, Inclisiran | Approved | Block PCSK9 protein → more LDL receptors | For statin-insufficient LDL control. Inclisiran (RNA-based) requires only 2 injections/year. |
| ColchicineLow-dose, 0.5mg daily | Approved | Anti-inflammatory (NLRP3 inhibition) | COLCOT and LoDoCo2 support inflammation-targeting in selected coronary disease populations. RICAD-specific benefit is not established, but the inflammatory biology makes it a topic to discuss with a clinician. |
| Senolytics (D+Q)Dasatinib + Quercetin | Experimental | Clears senescent cells from vessel walls | Radiation can contribute to cellular senescence. D+Q is being studied as a senolytic strategy, but human cardiovascular evidence remains early and it is not a standard RICAD treatment. |
| GLP-1 AgonistsSemaglutide (Ozempic/Wegovy) | Approved | Cardiac inflammation reduction + metabolic | SELECT trial: 20% MACE reduction in a selected non-diabetic, overweight/obese population with established CVD. Potential anti-inflammatory effects make this relevant to watch, but RICAD-specific evidence is limited. |
| CAR-T for AtherosclerosisEarly-stage research | Emerging | T cells engineered to clear arterial foam cells | Penn/Penn Medicine research. Conceptually revolutionary. Years from clinical use but the direction points toward reversing established disease, not just stopping it. |
| ZiltivekimabIL-6 ligand inhibitor: RESCUE trial | Clinical Trial | IL-6 pathway blockade → vascular inflammation | Targets an inflammatory pathway downstream of IL-6 signaling. Relevant to watch because radiation-associated vascular disease involves inflammation, but this is not established RICAD therapy. |
| CRISPR / Gene TherapyInclisiran → CRISPR-PCSK9 | Emerging | Permanent PCSK9 knockout via single treatment | Companies including Intellia Therapeutics are pursuing this direction. The appeal is a one-time LDL-lowering intervention with long-duration effect, but it is not approved for this use and remains a forward-looking area to watch. |
| Rapamycin (mTOR inhibition)Longevity off-label use | Off-label | mTOR inhibition → autophagy, anti-senescence | Used by some longevity physicians weekly (intermittent). May slow vascular aging and reduce plaque progression. Active research in aging context. |
| AI-Enhanced CAC ScreeningCleerly AI, Elucid | Approved | Deep learning plaque characterization | Advanced CCTA analysis can characterize plaque beyond a simple CAC score. Potentially useful for radiation-exposed survivors, but tool choice and clinical interpretation should come from the treating team. |
| Intravascular Lithotripsy (IVL)Shockwave Medical / Abbott TECTONIC | Approved | Sonic pressure waves fracture coronary calcium before stenting | RICAD plaques can be calcified and fibrotic, making IVL relevant to watch for calcified-lesion PCI. 2025 EMPOWER CAD and VICTORY trial data reported high procedural success with low short-term adverse events, though approach selection remains operator- and anatomy-dependent. |
| FLASH RadiotherapyPrevention: ultra-high dose rate RT | Emerging | Delivers radiation 300x faster than conventional RT → spares healthy cardiac tissue | Preclinical data suggests reduced endothelial injury and fibrosis vs. conventional RT. If the approach proves out clinically, it could reduce future treatment-related cardiovascular injury, but it remains investigational. Phase I/II trials are ongoing. |
| MetforminCardioprotective use in radiation survivors | Emerging Evidence | AMPK activation → reduced oxidative stress and endothelial inflammation | Under active discussion as a possible cardioprotective option in radiation-exposed breast cancer populations, but the human evidence is still mixed. Not guideline-standard for RICAD; treat it as an emerging topic to discuss with a clinician rather than a default survivor protocol. |
Scientists & Physicians Shaping the Conversation
These are researchers and clinicians whose work is often relevant to RICAD, cardio-oncology, prevention, imaging, and longevity. Inclusion here is for monitoring and context, not as a blanket endorsement of every view, recommendation, or public statement they make.
A prominent cardiologist and public voice on AI in medicine. His work on deep learning for cardiac imaging is relevant to earlier and better cardiovascular detection, including questions that matter for RICAD survivors.
A well-known physician in longevity and preventive cardiometabolic risk framing. His emphasis on ApoB, LP(a), and earlier intervention is relevant to how some survivors think about vascular prevention, even where RICAD-specific evidence remains incomplete.
A major researcher in coronary artery calcium scoring and CT angiography. His work on CAC progression and plaque characterization is highly relevant background for survivors trying to understand imaging, plaque burden, and surveillance.
A prolific cardio-oncology researcher with work on cardiovascular toxicity from cancer treatment. His publications are directly relevant to understanding RICAD mechanisms, risk, and management questions.
Focused on mitochondrial bioenergetics, oxidative stress, and cardiorenal mechanisms that help explain how vascular and cardiac injury can persist over time. Her work is relevant context for the mechanistic side of radiation-associated cardiovascular disease.
Known for work and advocacy around aging biology, NAD+ pathways, and sirtuins. While not RICAD-specific, some of his framing overlaps with questions about radiation, vascular aging, and repair; that makes him relevant to track, not automatically to adopt.
Studies That Changed How We Think
Trials, papers, and guidelines that shape how this site currently thinks about RICAD.
IC-OS/MASCC Clinical Practice Statement for Cardiovascular Disease in Adults With Cancer (Cardio-Oncology, 2026)
A new International Cardio-Oncology Society and MASCC statement gives cancer care providers practical guidance for identifying, preventing, and managing cardiovascular disease across treatment and survivorship. For RICAD, the important shift is operational: cardiovascular risk assessment and long-term follow-up belong inside cancer care, not as an optional referral years later.
Cardiac Substructure Dose Response After Lung Cancer Radiotherapy (Clinical Lung Cancer, 2026)
This review consolidates evidence that doses to cardiac substructures may predict post-radiotherapy cardiac risk better than whole-heart dose alone. It is especially useful for RICAD because coronary arteries, the heart base, and ventricular structures can receive very different doses even when mean heart dose looks acceptable.
AI Cardiovascular Risk Prediction From Breast-Radiotherapy Planning CT (Radiotherapy & Oncology / UBCO-BC Cancer, 2026)
Researchers reported an AI model that uses routine breast-radiotherapy planning chest CT plus clinical health-record variables to estimate cardiovascular risk. It is not a validated RICAD pathway yet, but it points toward opportunistic cardio-oncology screening from imaging that oncology teams already collect.
EORTC 22922/10925 Final 20-Year IM-MS Nodal Irradiation Results (CA: A Cancer Journal for Clinicians / ESTRO, 2026)
With 4,004 patients and median 22.2-year follow-up, elective internal mammary and medial supraclavicular nodal irradiation reduced breast-cancer mortality but did not improve overall survival. The late emergence of non-breast-cancer deaths is a survivorship warning: radiation benefit-risk analysis can change only after very long follow-up.
Long-Term Cardiovascular Risk After Contemporary Left-Sided Breast Radiation Therapy (JAMA Network Open, 2026)
A population-based Ontario cohort study of 76,586 women treated with external beam radiation therapy for unilateral breast cancer between 2002 and 2017. After a median 10.9 years of follow-up, 15-year first cardiovascular hospitalization did not differ significantly between left- and right-sided treatment (13.8% vs. 13.5%). The message is hopeful but precise: contemporary photon-based EBRT appears to have reduced the historical excess risk from left-sided breast radiation, but this does not erase risk for older mantle-field, mediastinal, internal mammary chain, or high-dose chest radiation survivors.
ESC/EACVI Multimodality Imaging Consensus for CAD/PAD in Cancer Patients (EHJ Cardiovascular Imaging, 2026)
A new European clinical consensus statement supports tailored multimodality imaging for cancer patients and survivors at risk of coronary and peripheral arterial disease. For RICAD, the importance is practical: survivors with prior chest radiation often need smarter selection among echo, CCTA, vascular imaging, nuclear testing, and CMR rather than a one-size-fits-all pathway.
Left-Ventricular Dose and Late Heart Failure After Post-Op RT for Thymic Malignancies (Radiother Oncol, 2026)
A 101-patient cohort with median 10-year follow-up found that higher mean left-ventricular dose predicted later heart-failure risk after postoperative thoracic radiation. This is not a pure RICAD trial, but it strengthens the case for substructure-based dose awareness and long-term ventricular surveillance in chest-radiation survivors.
COLCOT Trial: Colchicine in Coronary Artery Disease (NEJM, 2019)
Low-dose colchicine (0.5mg/day) reduced MACE by 23% in post-MI patients. It helped validate anti-inflammatory therapy as a cardiovascular intervention beyond lipid lowering. RICAD involves chronic inflammation and fibrosis, but direct RICAD-specific outcome evidence remains limited.
SELECT Trial: Semaglutide in Cardiovascular Prevention (NEJM, 2023)
Semaglutide reduced major cardiovascular events by 20% in non-diabetic, overweight patients with established CVD. The mechanism appears to involve direct anti-inflammatory effects on the arterial wall: independent of weight or glucose effects.
Radiation-Induced Cardiovascular Disease: ESC Cardio-Oncology Guidelines (2022)
The first comprehensive European Society of Cardiology guidelines specifically for cardiovascular complications of cancer treatment. Covers screening timelines, risk stratification, and management recommendations for RICAD. This is a core reference point for the site, not the only authority.
Clearance of Senescent Cells Reverses Radiation-Induced Damage (Nature Medicine, 2021)
Senolytic treatment reversed radiation-induced physical dysfunction and metabolic disruption in mouse models. Provides direct mechanistic support for using senolytics in RICAD survivors. Translational work is ongoing in humans.
Radiation-Induced Coronary Artery Disease: Points to Remember (PMC, 2025)
A 2025 clinical review presenting RICAD as a distinct and increasingly recognized form of CAD. Key findings include chronic inflammation and fibrosis, higher risk in several radiation-exposed survivor groups, and plaque patterns that may differ from typical atherosclerosis. The review discusses PCI with drug-eluting stents as an important option when technically feasible, while emphasizing that revascularization decisions remain anatomy- and patient-specific.
Cardioprotection for Radiation-Induced Heart Disease in Breast Cancer (Frontiers in Pharmacology, 2025)
A comprehensive 2025 review of pharmacological strategies for primary and secondary cardioprotection in patients receiving chest radiotherapy. Highlights statins, PCSK9 inhibitors, colchicine, GLP-1 agonists, and metformin as the most evidence-backed options. Emphasizes that concurrent chemotherapy (especially anthracyclines and trastuzumab) amplifies radiation-related vascular damage, and that RICAD risk assessment must account for the full treatment history, not just radiation dose alone. Key message: cardioprotection should begin before radiation starts, not after cardiovascular disease appears.
Trial Watchlist for Cancer-Survivor Cardiovascular Care
Curated from ClinicalTrials.gov and sponsor disclosures. These are not presented as RICAD-specific trials or guaranteed options for survivors. Verify status, location, and eligibility directly with the trial team.
Radiotherapy vs. Catheter Ablation for Ventricular Tachycardia (NCT06360939)
Compares stereotactic body radiotherapy (SBRT) to catheter ablation for ventricular tachycardia in structural heart disease. It is relevant to the cardio-oncology watchlist because some cancer survivors develop cardiomyopathy or arrhythmia risk after treatment, but prior radiation exposure and cumulative dose require careful specialist review.
Echo-Only vs. Echo + Contrast for TAVI Guidance (NCT07317804)
Evaluates whether echocardiography alone is sufficient to guide transcatheter aortic valve implantation, versus echo plus contrast imaging. It is relevant to watch because aortic stenosis can be a late complication of chest radiation, but this trial is not framed as a RICAD-specific study and is currently listed as not yet recruiting.
TECTONIC CAD: Intravascular Lithotripsy for Severe Coronary Calcification (Abbott)
Abbott initiated this IVL trial in March 2025 to evaluate its investigational lithotripsy system for severe coronary calcification. It is relevant to watch because radiation-associated plaques can be calcified and fibrotic, but it is not a RICAD-specific trial and any PCI strategy depends on anatomy, operator judgment, and patient-specific risk.
Relugolix vs. Leuprolide: Cardiac Effects in Prostate Cancer (NCT06330805)
Phase 2 trial directly comparing how two androgen deprivation therapy (ADT) agents affect cardiac function in prostate cancer patients. Relugolix (GnRH antagonist) has shown a more favorable cardiovascular safety profile than leuprolide (GnRH agonist) in earlier data. Cancer survivors are disproportionately affected by cardiotoxic treatment effects: this trial advances the cardio-oncology evidence base for choosing ADT agents with heart health in mind.
Get meaningful RICAD updates without the noise.
The RICAD Support Digest is an interest-list project for monthly-if-worthy plain-language updates on radiation-induced cardiovascular and vascular disease after cancer treatment: research, imaging, prevention, and practical questions to ask your doctor. If there is nothing meaningful to report, we skip the month. No spam. Not medical advice.